Sanofi, a French multinational pharmaceutical company, agreed to acquire Amunix Pharmaceuticals, an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer, for $1bn. “This acquisition demonstrates our ongoing commitment to investing in promising research and discovery platforms. The Amunix technology platform utilizes a next generation smart biologics approach to precisely tailor-deliver medicines to become active only in tumor tissues while sparing normal tissues, thus bringing the promise of more effective and safer treatment options for cancer patients. We are excited to rapidly advance Amunix’s promising pipeline and to combine their innovative candidate medicines with complementary molecules in Sanofi’s immuno-oncology portfolio,” John Reed, Sanofi Global Head of Research & Development.